Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise
Tirzepatide Showed Superiority To Ozempic In Clinical Trials
Executive Summary
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
You may also be interested in...
Obesity Market Potential Is Huge, But Access To Drugs An Increasing Challenge
Despite double-digit weight loss across several drugs presented at ADA, experts note access to obesity therapies will be constrained without outcomes data to justify their widespread use and cost.
Lilly’s Mounjaro Shows Strong Sales And Data As Firm Eyes Obesity Market
Excluding COVID-19 antibodies, the company said revenues for the quarter increased by 10% while volume increased by 18%, and sales of Mounjaro came in stronger than analysts anticipated.
Weight Watchers Weighs In On Obesity Drugs, Offering Valuable Validation
WW International’s decision to move into pharmaceutical weight management could build commercial momentum for Novo Nordisk’s Wegovy and Lilly’s Mounjaro.